Publication Name	World Journal of Obstetrics and Gynecology
Manuscript ID	3678
Country	Italy

Received	2013-05-14 09:47
Peer-Review Started	2013-05-14 15:46
To Make the First Decision	2013-06-09 10:15
Return for Revision	2013-06-18 13:18
Revised	2013-06-29 01:09
Second Decision	2013-07-05 11:58
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-07-05 13:13
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-09-15 10:37
Publish the Manuscript Online	2013-11-17 20:09

ISSN	2218-6220 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Urology & Nephrology
Manuscript Type	Editorial
Article Title	Mirabegron, a novel, non-antimuscarinic drug for the overactive bladder: An up-to-dated review
Manuscript Source	Invited Manuscript
All Author List	Emilio Sacco and Riccardo Bientinesi
Funding Agency and Grant Number
Corresponding Author	Emilio Sacco, MD, PhD, Urologic Clinic, “Agostino Gemelli” Hospital, Catholic University Medical School of Rome, Largo F Vito 1, 00168 Rome, Italy. emilio.sacco@gmail.com
Key Words	Mirabegron; β3-adrenoceptor agonist; Antimuscarinics; Overactive bladder; Urinary incontinence
Core Tip	Mirabegron is a first-in-class, potent β3-adreno?ceptors agonist that has been proven effective in the treatment of overactive bladder (OAB) based on multiple randomized multinational trials. The safety-tolerability profile of treatment with mirabegron has been extensively studied. The placebo-like incidence of classic adverse effects caused by antimuscarinics should improve long-term adherence to treatment with this new drug. Mirabegron can be an alternative in patients with contraindications to antimuscarinics or that discontinued previous antimuscarinic therapy. An updated review of the rationale of β3-agonism for OAB treatment and evidence of efficacy and safety of mirabegron is presented.
Publish Date	2013-11-17 20:09
Citation	Sacco E, Bientinesi R. Mirabegron, a novel, non-antimuscarinic drug for the overactive bladder: An up-to-dated review. World J Obstet Gynecol 2013; 2(4): 65-73
URL	http://www.wjgnet.com/2218-6220/full/v2/i4/65.htm
DOI	http://dx.doi.org/10.5317/wjog.v2.i4.65

Full Article (PDF)	WJOG-2-65.pdf
Manuscript File	3678-Review.docx
Answering Reviewers	3678-Answering reviewers.pdf
Copyright License Agreement	3678-Copyright assignment.PDF
Non-Native Speakers of English Editing Certificate	3678-Language certificate.pdf
Peer-review Report	3678-Peer reviews.pdf
Scientific Editor Work List	3678-Scientific editor work list.doc